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Efficient neutralization of HIV is a primary
goal both for therapeutic and prophylac-
tic HIV vaccines based on induction of
neutralizing antibodies (NAbs) (1, 2). Neu-
tralization capacity of NAbs correlates with
their affinity to HIV-1 gp120 envelope gly-
coprotein (3). In HIV-infected individuals,
early IgM antibodies have low affinity for
gp120 glycoprotein (3), which is slightly
compensated by their pentameric structure
and avidity to multivalent structures of the
virus. Corresponding IgG1 antibodies (3,
4), which appear later from IgM through
the CSR and SHM processes (3, 5), have
high affinity and specificity to gp120, but
low avidity due to monomeric structure of
IgG. The question is how to induce HIV-
specific NAbs with both high affinity and
avidity to gp120?
Anti-HIV IgG antibodies 2F5 and 2G12,
switched back to IgM isotype, showed
increased avidity and neutralization effi-
cacy (2). Dendritic antibody supramole-
cules (DAS) in one molecule combine high
specificity of IgG with high avidity of IgM
(6). It would be of interest to construct
such a DAS with IgM as a core, carry-
ing 10 anti-gp120 IgG monomers. Natural
monomeric anti-gp120 IgG1 antibodies (3,
4) not only have low avidity insufficient
for effective neutralization of HIV but may
also contribute to FcR-mediated infection
enhancement (7, 8). Does it mean that HIV
may use high-affinity IgG antibodies for
its own purposes? Fortunately, in nature
there exist some helpful network-like reg-
ulatory mechanisms with a key role of RF
antibodies (9).
Rheumatoid factor (RF) is an autoan-
tibody which specifically binds Fc region
of IgG (10, 11). Apart from pathologic
RF in rheumatoid arthritis (12), nat-
ural RF appears in many non-rheumatoid
states (13). Possible beneficial physiological
roles of RF include enhanced clearance of
immune complexes (ICs) (14), amplifica-
tion of IgG response to pathogens (15),
and enhancement of virus neutralization
(16, 17). RF can be induced in vivo in
a highly specific way either by secondary
immunization with protein antigens or in
response to immunization with the newly
formed ICs (10, 11). New antigenic deter-
minants, which appear in the Fc region
of IgG antibody upon antibody-antigen
complex formation, may strengthen the
specificity of RF (9).
The level of RF was significantly higher
in some of HIV-infected individuals com-
pared to control groups (18–22). RFs
were mainly IgA, IgM immunoglobu-
lins with specificity against anti-HIV IgG
(20). RF-mediated enhancement of anti-
HIV IgG neutralization activity was found
in the sera from MCTD patients (17).
Authors suggested that RF is promis-
ing for passive immunotherapy based on
NAbs (17).
Can RF play a key role in specific
enhancement of IgG-mediated neutraliza-
tion of HIV in vivo? Measurements of RF
level both in long-term non-progressors
(23) and dual-infected individuals (24)
might give some clues. Repeated immu-
nization of uninfected macaques with HIV-
1 gp120 glycoprotein may allow researchers
not only to track the kinetics of RF
induction but also to elucidate whether
neutralization-enhancing RF antibodies
can protect macaques against subsequent
challenge with SHIV. Repeated immuniza-
tion of SHIV-infected macaques with HIV-
1 gp120 glycoprotein might show whether
neutralization-enhancing RF antibodies
can prolong the asymptomatic period and
delay the onset of AIDS.
The level of RF is not stable and has a
tendency to decline during the acute phase
of HIV infection (22). Prolonged repeated
immunizations with gp120 (e.g., immu-
nizations every 3 weeks; the actual time
between immunizations will be adjusted
according to measurements of RF level
in patients) would be the solution to
keep the level of neutralization-enhancing
RF antibodies constantly high. Single-
administration vaccine (SAV) technol-
ogy, which is based on pulsatile release
of gp120 from biodegradable polymeric
microspheres, mimics repeated immuniza-
tion scheme, and allows vaccination to be
done in one shot (25, 26).
Patient-specific therapeutic HIV vac-
cines (1) even in simplified version, using
the only one gp120 variant formed after
completion of HIV population homoge-
nization process (27), can be performed via
repeated immunizations from biodegrad-
able polymeric microspheres under SAV
(25, 26) technology platform. Prophylac-
tic HIV vaccines can be based on the
variations of sequential scheme (28) for
prolonged pulsatile release of gp120 gly-
coproteins from biodegradable polymeric
microspheres in single-shot (25, 26) way
convenient for both patients and doctors.
Studies (15, 17) have shown the high
potential of neutralization-enhancing RF
antibodies, but several principal questions
arise:
(i) Can neutralization-enhancing RF anti-
bodies (NeRFa) be induced after
repeated immunization of humans
with recombinant gp120 glycoprotein?
(ii) Will the power of gp120 immuno-
gen design (29–31) combined with an
optimal vaccination regimen help the
induction of NeRFa?
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(iii) Could NeRFa help to improve the effi-
cacy of previous (32) and future HIV
vaccines based on induction of NAbs?
(iv) Might induction of NeRFa be a future
promising method not only against
malaria as suggested in Ref. (33), but
also against life-threatening viruses like
Ebola (34)?
Repeated immunization with gp120 gly-
coprotein might lead to prolonged induc-
tion of neutralization-enhancing RF anti-
bodies with a potential to be explored for
finding the ways to extend lives of HIV-
infected individuals and to stop current
HIV pandemic.
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